B
CYT

Bailard’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Bailard’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,900
Closed -$42K – 781
2022
Q2 		$42K Buy
+13,900
New +$35.5K ﹤0.01% 675

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's CYT Position: Q3 2022 in Review

Bailard sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2022, closing a stake of 13,900 shares — an estimated $42K sold.

Bailard first reported a position in CYT in Q2 2022 and held it in 1 quarter. The position peaked at $42K in Q2 2022. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • Bailard reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Bailard sold 13,900 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $42K.
  • Bailard first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Bailard's Cyteir Therapeutics, Inc. Common Stock position peaked at $42K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.